Approval · Notice of Compliance 26176 · 2021
COMBOGESIC: Notice of Compliance 26176
Issued June 30, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26176
- Date
- June 30, 2021
- Company
- BioSyent Pharma Inc.Mississauga, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling revisions - removal of child resistant packaging information as child resistant cartons will no longer be marketed. Addition of a 70 tablets package size.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COMBOGESIC | Not yet assigned | — |
Medicinal ingredients
- ACETAMINOPHEN 325 MG per TAB
- IBUPROFEN 97.5 MG per TAB